Promotion of Research and Innovation in Pharma MedTech sector (PRIP)

About this scheme

PRIP, the scheme for Promotion of Research and Innovation in Pharma MedTech, is the Department of Pharmaceuticals' bid to turn India from a volume manufacturer into a genuine research and development centre for medicines and medical devices. It sets out to speed up the discovery, development, and commercialisation of new drugs, encourage device innovation, knit together industry and academia, and pull the sector's growth model away from low-cost production toward original innovation.

The programme is sized at Rs. 5,000 crore overall, with equity-free support to individual projects running from Rs. 10 lakh to Rs. 5 crore. A defined slice goes to Strategic Priority Innovations, meaning products and technologies that tackle public-health problems the open market tends to ignore, such as neglected tropical diseases, rare diseases, and antimicrobial resistance. Applications were handled through the official portal at prip.pharma-dept.gov.in; the most recent round closed on 10 November 2025, so prospective applicants should check the portal for any future window.

Who can apply

• Only startups and MSMEs may apply.
• A project must already sit at Technology Readiness Level (TRL) 1, 2, or 3, the early proof-of-concept band, and aim to climb to TRL 5, where a technology is validated in a relevant setting.
• New medicines are in scope, including new chemical entities, new biological entities, and phytopharmaceutical drugs.
• Complex generics and biosimilars qualify.
• Novel medical devices count too, covering AI- and ML-driven devices, Software as a Medical Device (SaMD), Software in a Medical Device (SiMD), robotic devices, and new in-vitro diagnostics.
• Teaming up with established government academic or research institutions is welcomed, and proposals built on such collaboration are given preference.

Frequently asked questions